salicylates and Leukemic-Infiltration

EAE is a common animal model for multiple sclerosis (MS). Immunomodulatory treatments such as glatiramer acetate (GA, Copaxone) are beneficial in EAE but are not universally effective in the clinic. The Ras inhibitor farnesylthiosalycylic acid (FTS, Salirasib), efficiently ameliorate EAE as well. Here we demonstrate a synergistic beneficial effect of the combined GA and FTS treatment on EAE; 22.5% of the combined-treatment mice developed disease compared to 87.5%, 77.5% and 82.5% of mice treated with vehicle, GA and FTS, respectively, results supported by MRI, histological, immunological and biochemical data. Such a combined treatment may improve clinical outcome in MS patients.

Topics: Animals; Carrier Proteins; CD3 Complex; Cell Proliferation; Cytokines; Demyelinating Diseases; Disease Models, Animal; DNA Helicases; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Forkhead Transcription Factors; Glatiramer Acetate; Immunosuppressive Agents; Leukemic Infiltration; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Peptides; Poly-ADP-Ribose Binding Proteins; RNA Helicases; RNA Recognition Motif Proteins; Salicylates; Spinal Cord; Spleen; Statistics, Nonparametric; Time Factors